Your Wednesday Evening Leronlimab Update: The Mystery

New Post Public Reply Private Reply Replies (4) Message Board
Respert24
1,554
Your Wednesday Evening Leronlimab Update: The Mystery Meetings Edition

(Sponsored by an almost completed bottle of Pure Paso by J Lohr)

(Update: Completed)

Today we failed to get any sort of news out of the big UK meeting. It's still sort of early and maybe we get one of those odd 9:32pm press releases, but the betting public disagrees with this sentiment as we've seen the line move significantly in favor of no announcement today. Current odds for an announcement before the bell opens tomorrow are at a dismal 20-1.

Analysis: You have a better chance at curing Covid with Remdesivir than you do getting an update about the UK today. That being said, they asked for our information surrounding manufacturing, efficacy, and safety so they could review it prior to this meeting. That means they can, or maybe have, come to a conclusion about the validity of Leronlimab as a treatment for Covid. The hour could very well have been about shoring up the details and setting the expectations/executables for pulling the approval trigger. I feel like "pre BLA" was a deceiving way to explain this meeting. Every day we don't have to start another trial or hear about being denied approval is a very big deal. Logic says they would have said no by now if it was a no.

We are now a full day from the meeting with the FDA and still no update. Do they want to help us? Are they slow playing us? Do they even really know what Leronlimab is and what it can do? Does the lack of an update inadvertently give us an update as no news could be construed as good news? Did I spell inadvertently incorrectly and have to go back to fix it? How many questions can a guy ask in a row before it gets weird? Is it already weird? Who defines what weird is anyway?

Analysis: You've got a higher chance of Plasma becoming the standard of Covid care than you do of Leronlimab failing to get an approval. I think that since we haven't gotten bad news after all this time we can reasonably assume that we're in a decent/good position surrounding approval. On a call from what seems like 11 years ago, JL mentioned that Cytodyn had gone to the FDA asking for EUA something like 4 times from early in the Montefiore days to much later once EINDs were happening on the west coast as well. Every time they denied us. Yet here we are 3-4 weeks in with hopes still high.

SPEED ROUND!

NP & BP - It's all good between them. They were recently seen together at Nobu eating soba noodles from opposite ends of the noodle, Lady and the Tramp style.

NASDAQ - More like NAS-WHATTHEHECKISTHEHOLDUP amiright? Thank you, I'll be here all week. Tip your waitstaff.

SHAREHOLDER VOTE - Not unlike the bicycle dance scene from the movie RAD, this subject has become a lightning rod of opposing views. I think we can all agree that no matter the outcome, Cru Jones was basically the BMX version of Leronlimab. Scrappy, unknown but worthy, good at dancing on bikes, wins in the end. You get it.

MANUFACTURING - We likely can't squeeze more out of 2020 because it's late and outside of our 1.5mil vials already scheduled and paid for, Samsung is apparently contracted out. But next year is wide open like <insert Adam Feurstein mama joke here> and we should be able to negotiate a massive increase in production with those sweet, sweet Euros the UK soon throws at us.

MESSAGE BOARDS - Ihub is now 95% disingenuous dbags and I applaud those of you who have finally made the move here. YMB is a close terrible second, with that main difference being a few less bashers but far more political BSrs. This is clearly the best board and for that I'm grateful.

PREDICTIONS

I someday have a beach house or boat called "Twenty Nine Cents", named after the cheapest CYDY shares I was able to acquire. Leronlimab is as well known to the public as drugs like the Z-Pack or Allegra. I become an insufferable wine snob as my wine budget grows to unheard of proportions. But best of all, people around the world stop dying needlessly from Covid and the tide changes for the better. Hold onto your shares. Great things are ahead and whether it's tomorrow or in a month we have yet to have any evidence that Leronlimab doesn't have the goods.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cracking the Code of America's Delivery Addiction

Updated Category News Views 4

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 6

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading
Machine Grabs Prime Dallas Property Amid Apartment Boom

Updated Category News Views 7

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 5

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 8

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 6

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 7

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
Compass Unveiled: Power Revolution in Private Equity

Updated Category News Views 8

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 8

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 8

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Update: Futures Rise as Key Stocks Gain Momentum

Updated Category News Views 109

Market Overview U.S. stock futures have shown an upward trend following a positive closing on the previous trading day. Major benchmark indices are seeing gains, leading investors to keep a close eye on market movements as the holiday season approaches. Index Performance In the week prior, the S&P 500 faced a slight decline of 0.37%, with other indices like the Nasdaq...

Continue Reading
Faye Celebrates Recognition Among Fastest-Growing Companies

Updated Category News Views 248

Faye's Remarkable Achievement in Business Growth Faye, a distinguished leader in the field of software strategy, deployment, and management, has reached an exciting milestone. The company has earned a spot on the prestigious 2025 Inc. Regionals: Pacific list, which honors the fastest-growing private companies in the Pacific region. This recognition not only showcases...

Continue Reading
Shinjiro Koizumi's Vision for Change and Future Diplomacy

Updated Category News Views 322

Shinjiro Koizumi's Game-Changer Status in Japanese Politics At a pivotal moment for Japan’s political scene, Shinjiro Koizumi is stepping into the spotlight. This guy isn’t your usual politicos’ fare—he’s young, energetic, and poised to bring a fresh vibe to a landscape crowded with seasoned players like Shigeru Ishiba and Sanae Takaichi. If you’re looking for...

Continue Reading
Doman Building Materials Expands Offerings with New Notes

Updated Category News Views 188

Doman Building Materials Group Ltd. Enhances Financial Strategy Doman Building Materials Group Ltd. (“Doman” or the “Company”) (TSX: DBM) has successfully completed a private placement offering, raising $170 million through the sale of senior unsecured notes. This notable move marks an important step in the Company’s ongoing strategy to optimize its financial...

Continue Reading
Enhancing Your Home's Air Quality: Tips for Healthier Living

Updated Category News Views 46

Enhancing Your Home's Air Quality Petri Plumbing, Heating, Cooling & Drain Cleaning emphasizes that homeowners can celebrate National Indoor Air Quality Month by implementing straightforward strategies to improve their indoor air conditions. Acknowledge the Problem "In October, we're supposed to be scared of ghosts and goblins but not of our indoor air," remarked Michael...

Continue Reading